Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Aeglea Biotherapeutics
901 S. MoPac Expressway
Barton Oaks Plaza One, Suite 250
Austin, TX 78746
Phone: 512-942-2935
http://aegleabio.com

Aeglea was founded in 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. Aeglea's pipeline of engineered human enzymes includes AEB1102, which we expect will enter into clinical trials in both hyperargininemia and cancer. In addition, three additional drug candidates are in pre-clinical development: AEB4104, which degrades homocystine, is being evaluated as a potential treatment for the inborn error of metabolism homocystinuria; AEB3103, which degrades cysteine/cysteine, is being evaluated for its ability to increase oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies; and AEB2109, which degrades methionine, is being evaluated for the treatment of solid tumors.

Key Contact
Name
David G. Lowe
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
03/23/15 $44,000,000 Series B Ally Bridge Group
Cowen Investments
Jennison Associates
Lilly Ventures
Novartis Venture Funds
OrbiMed Advisors
RA Capital
Rock Springs Capital
UT Horizon Fund
Venrock
undisclosed